Medicinova/ US58468P2065 /
| 20/09/2024 21:01:28 | Chg. +0.17 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 1.86USD | +10.06% | 479 Turnover: 895.11 |
-Bid Size: - | -Ask Size: - | 1.95 | 1.79 |
GlobeNewswire
30/08
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Paten...
GlobeNewswire
20/06
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Inves...
GlobeNewswire
05/06
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Preventio...
GlobeNewswire
03/06
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Pati...
GlobeNewswire
28/05
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of t...
GlobeNewswire
20/05
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Preventio...
GlobeNewswire
14/05
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment...
GlobeNewswire
07/05
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-1...
GlobeNewswire
03/04
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Gliobla...
GlobeNewswire
27/03
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treat...
GlobeNewswire
21/03
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentatio...
GlobeNewswire
12/03
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung I...
GlobeNewswire
17/01
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment...
GlobeNewswire
22/12/2023
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accep...
GlobeNewswire
07/12/2023
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for t...
GlobeNewswire
20/11/2023
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Gliob...
GlobeNewswire
27/10/2023
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment...
GlobeNewswire
11/10/2023
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudi...
GlobeNewswire
28/09/2023
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medi...
GlobeNewswire
18/08/2023
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation...
GlobeNewswire
17/08/2023
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for ...
GlobeNewswire
16/08/2023
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Scler...
